Progress has been made in elucidating the immunological pathways involved in morphea.

Disease monitoring by reliable and sensitive outcome measures is improved by the localized scleroderma cutaneous assessment tool (LoSCAT); however, especially for deep involvement, additional validated outcome measures are required.

This review provides two state-of-the-art algorithms that guide care providers with regard to (i) diagnostic work-up and disease monitoring, and (ii) treatment of morphea and eosinophilic fasciitis.